IRVINE, Calif. — March 9, 2023 — Immunis, Inc., a private biotechnology company with a novel treatment for age and disease-related immune deficits, announces that its Research Scientist, Scott Greilach, Ph.D., will present at the Festival of Biologics in San Diego. With hundreds of world-class speakers, this three-day conference dissects the infrastructure of innovative biologics including discovery, development, manufacturing, pricing and market access. The conference’s goal is to harness the expertise from individuals in pharma, biotech and academic sectors to tackle the commercial challenges of bringing new therapies to market.

Dr. Greilach is thrilled to be part of a conference that serves as a bridge between academia and industry. The Festival of Biologics provides a one-of-a-kind platform to discuss Immunis’ investigational secretome product, STEM, which is currently being studied in several models of disease at multiple universities. Most importantly, Dr. Greilach will highlight Immunis’ Phase 1/2a clinical trial, where STEM is being investigated for safety and efficacy in patients with muscle atrophy. Dr. Greilach is looking forward to spreading his enthusiasm on the prospects of the stem cell secretome in biomedicine.

About Festival of Biologics

The vision of Festival of Biologics is to unite senior biologics professionals in a collaborative space to advance industry and improve human health. For more information please visit: https://www.terrapinn.com/conference/festival-of-biologics-usa/index.stm

About Immunis Inc.

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The STEM product line leverages Immunis’ leading-edge capabilities in stem cell technologies to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ IMM01-STEM Phase 1/2a trial please visit: www.immunisbiomedical.com

About STEM-MYO

Immunis’ FDA-awarded Phase 1/2a clinical trial is an open-label dose escalation study to assess the safety and tolerability of IMM01-STEM in elderly participants with muscle atrophy associated with knee osteoarthritis. Up to 18 patients will be enrolled in the trial and randomly assigned to an IMM01-STEM dose cohort. Treatment will be administered in the form of intramuscular injections twice a week for four weeks (8 injections total). Male or female patients are eligible for the study if they satisfy the following criteria: (1) 50 to 75 years of age at the time of signing the informed consent, (2) have a grade 2 or 3 knee osteoarthritis as defined by Kellgren-Lawrence analyses, (3) have quadricep weakness (<7.5N/kg), (4) can ambulate >50 feet unassisted, (5) are negative for human immunodeficiency virus, hepatitis B surface antigen (HBsAg), and hepatitis C at the Screening Visit and (6) have a body mass index (BMI) of <40kg/m². For additional information about Immunis’ trial participant qualifications, please visit:  www.immunisbiomedical.com

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.